Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Bechara

Vascular Surgery Maywood, IL Medical Doctor

NPI 1639357585 CMS profile 74548

2160 S 1St Ave, Maywood, IL 60153

Open in the dashboard

General payments

$199,097

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Bechara of Maywood, IL is reported in the CMS Open Payments database as having received $199,097 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,365 24
2024 General $14,478 29
2023 General $29,035 51
2022 General $23,380 46
2021 General $28,199 61
2020 General $35,315 35
2019 General $60,327 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Bechara
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Carlos Bechara were reported at $8,365. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Carlos Bechara Vascular Surgery median Middle half National median
2019 $60,327 $796 $226–$2,363 $163
2020 $35,315 $348 $118–$1,110 $114
2021 $28,199 $471 $158–$1,421 $132
2022 $23,380 $725 $222–$2,183 $149
2023 $29,035 $836 $257–$2,440 $160
2024 $14,478 $909 $252–$2,619 $164
2025 $8,365 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $90,512 105 payments
  2. Cook Incorporated $75,283 41 payments
  3. Penumbra, Inc. $17,400 32 payments
  4. Cook Medical LLC $11,304 92 payments
  5. Wilson Cook Medical Incorporated $1,240 1 payment
  6. Medtronic, Inc. $749 20 payments
  7. Medtronic Vascular, Inc. $589 4 payments
  8. Cardiovascular Systems Inc. $527 13 payments
  9. Bolton Medical Inc $439 7 payments
  10. Shockwave Medical, Inc $148 1 payment
  11. Other $905 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,240 18 payments
  2. Honoraria $51,660 6 payments
  3. Consulting Fee $36,568 25 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $25,790 14 payments
  5. Food and Beverage $16,241 213 payments
  6. Travel and Lodging $13,640 52 payments
  7. Grant $2,901 5 payments
  8. Education $57 2 payments
Products named General payments · program years 2019–2025
  1. EXCLUDER AAA Endoprosthesis $36,680 12 payments
  2. COOK $30,733 18 payments
  3. TAG Thoracic Endoprosthesis $19,440 5 payments
  4. Product in Development $14,441 13 payments
  5. Cook Medical Zenith $12,783 9 payments
  6. Indigo System $12,529 22 payments
  7. Cook Medical AFEN $12,330 12 payments
  8. Zenith $11,910 17 payments
  9. GORE VIABAHN VBX Balloon Expandable Endo $9,083 13 payments
  10. GORE EXCLUDER Iliac Branch Endoprosthesis $5,126 7 payments
  11. Other $48,301 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

35

Median for Vascular Surgery: 122

Drug cost

$417

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 35 $417

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$113,224

Medicare's payments for the services billed

Medicare patients

506

Average age 74

Services billed

896

231 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 52%
Diabetes 46%
Chronic kidney disease 45%
Heart failure 39%
Atrial fibrillation 33%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record